Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × darolutamide × 30 days × Clear all

Sponsor

Conditions

Prostatic Neoplasms 13 Biochemically Recurrent Prostate Cancer 2 Urogenital Neoplasms 1 Urogenital Diseases 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Non-metastatic Castration-resistant Prostate Cancer 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Male Urogenital Diseases 1 High-Risk Localized Prostate Cancer 1 Granulosa cell tumor of the ovary 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

pembrolizumab 20 Specimen Handling 12 Paclitaxel 11 Magnetic Resonance Spectroscopy 11 Carboplatin 11 Biopsy 10 olaparib 7 Gemcitabine 5 Capecitabine 5 130-nm albumin-bound paclitaxel 5 eribulin 4 Taxes 4 Doxorubicin 4 X-Rays 3 Nivolumab 3 Cyclophosphamide 3 Cisplatin 3 tucatinib 2 sargramostim 2 liposomal doxorubicin 2 durvalumab 2 ceralasertib 2 Trastuzumab 2 Standard of Care 2 Platinum 2 Immunoglobulin G 2 Fulvestrant 2 Drug Therapy 2 Docetaxel 2 Colony-Stimulating Factors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡